Pharmaceutical Company CEO Developing $100 Alternative To EpiPen After 'Shameful' Price Hike
September 4, 2016
Mark Baum, CEO of Imprimis Pharmaceuticals who previously came out with a $1 alternative to Martin Shkreli's AIDS drug after 5000% price hike, is now going to take on Mylan and is plotting to offer a $100 EpiPen alternative.

Mark Baum / Imprimis Pharmceuticals
Baum believes the relentless EpiPen price hikes are "shameful" and plans to have a compounded version of the allergy treatment by the end of the year.
"I don't need to make $19 million a year," Baum said, referring to the big pay package Mylan's CEO Heather Bresch took home last year.
"Tonight when I go home I'm going to eat a nice piece of fish and the fish I eat isn't any better or worse than what she is going to eat."
Dogs Are Forced To Wear The Things They Steal — And It’s Hilarious
She Came To America With Almost Nothing — Now Her Diner Draws Crowds From Across The Country
A Woman Stepped Up When A Little Boy’s World Was Turned Upside Down
Man Visits Google Maps Pin Labeled 'Friendly Black Cat' And Finds Exactly What It Promised
Neighbor Steps In To Give Boy Without A Dad A Birthday To Remember
Sleepy Owl Discovered Resting On Shelf Inside New York Antique Store
This ‘Sloth-Like’ Lab Failed Guide Dog Training — And Found His True Calling
She Secretly Left Outfits For An Elderly Couple's Porch Goose… Then A Package Arrived That Left Her In Tears
Giant Sea Serpent Appears On Cabo Beach
Every Night I Watch My Neighbor's Dog Go Upstairs To Bed Like This
Viral Video Shows Mom’s Priceless Reaction When ‘Airbnb’ Turns Out To Be Daughter’s Home
